Page 199 - Eceptor News Today

In a recent study, researchers develop a new high-throughput assay that allows for rapid screening of potential inhibitors.

Recently, scientists have developed a bacterial two-hybrid (B2H) system to study the PPIs of SARS-CoV-2 in a heterologous non-eukaryotic system. This study is available on the bioRxiv* preprint server. Put simply, the B2H system could be used to analyze the SARS-CoV-2 proteome.

A new paper shows that human TLR3, TLR7, and TLR8 receptors are activated with naturally occurring RNA, but this is eliminated once modified nucleosides such as m5C, m6A, m5U s2U, or pseudouridine are incorporated.

A recent preprint discusses the antibody response to the nucleic acid vaccines against SARS-CoV-2 when administered to children aged 7-11 years.

A new paper discusses a new antibody with potent neutralizing activity against the ancestral SARS-CoV-2 strain, as well as newer variants of SARS-CoV-2.

A new study published in Developmental Cell investigates S-acylation of the SARS-CoV-2 S protein.

In a recent study, the structural dynamics of the SARS-CoV-2 M protein are studied at temperatures of 10-50 ˚C using molecular dynamics simulations.

The results of Phase I clinical trials for two new COVID-19 vaccine candidates based on recombinant RDB proteins are reported.

A new study from a team of researchers at the University of Pennsylvania examines the role played by lipids in this disease.

A new study published in the journal Nature attempted to investigate memory B cell evolution 5 months after vaccination with mRNA vaccines such as Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) in SARS-CoV-2 naïve individuals. The study explored various aspects of memory B cell antibody response like neutralizing response, affinity, epitope targeting, and neutralizing breadth.